Ibuprofen (Synonyms: 布洛芬; (±)-Ibuprofen)

目錄號: HY-78131 純度: 99.97%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南

摩爾計算器

Ibuprofen ((±)-Ibuprofen) 是一種口服有效的 COX-1 選擇性抑制劑，IC₅₀ 值為 13 μM。Ibuprofen 抑制細胞增殖、血管生成，并誘導(dǎo)細胞凋亡 (apoptosis)。Ibuprofen 是一種非甾體抗炎試劑和一氧化氮 (NO) 供體。Ibuprofen可用于疼痛、腫脹、炎癥、感染、免疫學(xué)、癌癥的研究。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Ibuprofen Chemical Structure

CAS No. : 15687-27-1

1. 客戶無需承擔(dān)相應(yīng)的運輸費用。

2. 同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價格	是否有貨
10 mM * 1 mL in DMSO	￥500	In-stock
500 mg	￥400	In-stock
1 g	￥500	In-stock
5 g	￥1050	In-stock
10 g		詢價
50 g		詢價

or 大包裝詢價

* Please select Quantity before adding items.

Customer Review

Other Forms of Ibuprofen:

MCE 顧客使用本產(chǎn)品發(fā)表的 15 篇科研文獻

•Cell Rep. 2019 Dec 17;29(12):3847-3858.e5. [Abstract]
•Chemosphere. 2019 Jun;225:378-387. [Abstract]
•Phytomedicine. 1 September 2022, 154427.
•EMBO Rep. 2022 Apr 11;e53932. [Abstract]
•Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
•Biochem Pharmacol. 2024 Aug 9:116478. [Abstract]
•J Neurosci. 2024 Jul 17:e0740242024. [Abstract]
•Inflammopharmacology. 2023 Nov 24. [Abstract]
•Neuropharmacology. 2022 Jul 11;109191. [Abstract]
•Cells. 2022, 11(12), 1870.
•Int J Mol Sci. 2021 Nov 22;22(22):12597. [Abstract]
•Sci Rep. 2020 Oct 2;10(1):16383. [Abstract]

•J Appl Toxicol. 2024 Jun 5. [Abstract]
•Bioresour Technol Rep. 2023 Nov 10, 101696.
•Bioresour Technol Rep. 2023 Dec, 24, 101619.

Ibuprofen 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 COX 亞型特異性產(chǎn)品:

查看所有亞型

COX COX-1 COX-2 COX-3

查看 Parasite 亞型特異性產(chǎn)品:

查看所有亞型

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

生物活性
純度 & 產(chǎn)品資料
參考文獻

生物活性

Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC₅₀ value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers^[1]^[2]^[5]^[8].

IC₅₀ & Target^[1]

COX-1

13 μM (IC₅₀)

COX-2

370 μM (IC₅₀)

細胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
Bel-7402	IC₅₀	> 100 μM Compound: Ibuprofen	Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
Bel7402/5-FU	IC₅₀	> 100 μM Compound: Ibuprofen	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
BGC-823	IC₅₀	> 50 μM Compound: Ibuprofen	Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
Caco-2	IC₅₀	> 50 μM Compound: Ibuprofen	Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
CHO	IC₅₀	200 μM Compound: 1	Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA	[PMID: 20503989]
CHO	IC₅₀	200 μM Compound: 1	Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA	[PMID: 21873070]
COS-7	IC₅₀	> 1000 μM Compound: Ibuprofen	Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
HCT-116	IC₅₀	448 μM Compound: IB	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 20171760]
HCT-15	IC₅₀	> 1000 μM Compound: Ibuprofen	Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
HT-29	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	552 μM Compound: IB	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 20171760]
Huh-7	IC₅₀	37.2 μM Compound: Ibu	Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 26810835]
K562	IC₅₀	> 1000 μM Compound: Ibuprofen	Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
L02	IC₅₀	> 100 μM Compound: Ibuprofen	Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
MCF7	IC₅₀	> 50 μM Compound: 6	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35468536]
MCF7	IC₅₀	> 50 μM Compound: Ibuprofen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
MCF7	IC₅₀	92.14 μM Compound: Ibuprofen	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
MDA-MB-231	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
Neutrophil	IC₅₀	12.1 μM Compound: Ibuprofen	Immunomodulatory activity in polymorphoneutrophils assessed as inhibition of luminol-induced oxidative burst by chemiluminescence assay Immunomodulatory activity in polymorphoneutrophils assessed as inhibition of luminol-induced oxidative burst by chemiluminescence assay	[PMID: 18950230]
Neutrophil	IC₅₀	27.53 μM Compound: ibuprofen	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP-indcued superoxide production after 5 mins Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP-indcued superoxide production after 5 mins	[PMID: 20839880]
Neutrophil	IC₅₀	32.55 μM Compound: ibuprofen	Antiinflammatory activity in human neutrophils assessed as fMLP-induced superoxide release after 5 mins by spectrometry Antiinflammatory activity in human neutrophils assessed as fMLP-induced superoxide release after 5 mins by spectrometry	[PMID: 17822293]
PANC-1	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
PC-3	IC₅₀	> 1000 μM Compound: Ibuprofen	Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
PC-3	IC₅₀	> 50 μM Compound: Ibuprofen	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
RAW264.7	IC₅₀	0.39 μM Compound: Ibuprofen	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA	[PMID: 28408221]
RAW264.7	IC₅₀	0.86 μM Compound: Ibuprofen	Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay	[PMID: 24656662]
RAW264.7	IC₅₀	14.4 μM Compound: Ibuprofen	Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in IL1beta protein expression level after 24 hrs by ELISA Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in IL1beta protein expression level after 24 hrs by ELISA	[PMID: 34890996]
RAW264.7	IC₅₀	1483.87 μM Compound: Ibuprofen	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production by ELISA	[PMID: 28408221]
RAW264.7	IC₅₀	2.1 μM Compound: Ibuprofen	Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in TNFalpha protein expression level after 24 hrs by ELISA Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in TNFalpha protein expression level after 24 hrs by ELISA	[PMID: 34890996]
RAW264.7	IC₅₀	3309.84 μM Compound: Ibuprofen	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	[PMID: 28408221]
RAW264.7	IC₅₀	54.5 μM Compound: Ibuprofen	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method	[PMID: 28561586]
SK-LU-1	IC₅₀	90.61 μM Compound: Ibuprofen	Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
TERT-RPE1	IC₅₀	> 40 μM Compound: 6	Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35468536]
U-251	IC₅₀	> 1000 μM Compound: Ibuprofen	Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
UACC-903	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
UACC-903	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
UACC-903	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]

體外研究
(In Vitro)

Ibuprofen（24 小時）抑制 COX-1 和 COX-2 活性，IC₅₀ 值分別為 13 μM 和 370 μM^[1]。
Ibuprofen (500 μM, 48 小時) 抑制細胞增殖和血管生成，并誘導(dǎo) AGS 細胞 (腺癌胃細胞系) 凋亡^[2]。
Ibuprofen (500 μM, 48 小時) 下調(diào) AGS 細胞中 Akt、VEGF-A、PCNA、Bcl2、OCT3/4 和 CD44 基因的轉(zhuǎn)錄，但上調(diào)野生型 P53 和 Bax 基因的 RNA 水平^[2]。
Ibuprofen (500 μM, 24 小時) 可恢復(fù)微管重組、微管依賴性細胞內(nèi)膽固醇轉(zhuǎn)運，并誘導(dǎo)囊性纖維化 (CF) 細胞模型和原代 CF 鼻上皮細胞中微管延伸至細胞周圍^[3]。
Ibuprofen（500 μM，24 小時）通過光敏化過程增強 MCF-7 細胞和 MDA-MB-231 細胞中紫外線誘導(dǎo)的細胞死亡^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	AGS cells
Concentration:	100-1000 μM
Incubation Time:	24 h, 48 h
Result:	Inhibited AGS cell viability with IC₅₀ values of 630 μM (trypan blue staining, 24 h), 456 μM (neutral red assay, 24 h), 549 μM (trypan blue staining, 48 h) and 408 μM (neutral red assay, 48 h).

體內(nèi)研究
(In Vivo)

Ibuprofen（300 mg/kg；口服；每日一次，連續(xù) 14 天）在產(chǎn)后乳腺癌模型中減緩了整體腫瘤生長，增強了抗腫瘤免疫特性，且沒有不良的自身免疫反應(yīng)^[5]。
Ibuprofen（60 mg/kg；ih；每隔一天一次，持續(xù) 15 天）可降低奧沙利鉑誘發(fā)的慢性周圍神經(jīng)病變大鼠模型中發(fā)生神經(jīng)病變的風(fēng)險^[6]。
Ibuprofen（20 mg/kg；口服；每 12 小時一次，共 5 次）會減少肌肉生長（平均肌纖維橫截面積），但不影響岡上肌腱對運動的適應(yīng)性調(diào)節(jié)^[7]。
Ibuprofen（35 mg/kg；口服；每日兩次）可減輕大鼠慢性肺部感染模型對銅綠假單胞菌的炎癥反應(yīng)^[8]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Syngeneic (D2A1) orthotopic Balb/c mouse model of PPBC (postpartum)^[5]
Dosage:	300 mg/kg, daily for 14 days
Administration:	Fed in animal feedings (added to pulverized standard chow and mixed dry, then mixed with water, made into chow pellets and dried thoroughly)
Result:	Suppresed tumor growth, reduced presence of immature monocytes and increased numbers of T cells. Enhanced Th1 associated cytokines as well as promoted tumor border accumulation of T cells.

Animal Model:	Oxaliplatin?induced peripheral neuropathy^[6]
Dosage:	60 mg/kg, every second day for 15 days
Administration:	Subcutaneous injection
Result:	Lowered sensory nerve conduction velocity (SNCV).

Clinical Trial

分子量

206.28

Formula

C₁₃H₁₈O₂

CAS 號

15687-27-1

性狀

固體

顏色

White to off-white

中文名稱

布洛芬；異丁苯丙酸；異丁洛芬

運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

溶解性數(shù)據(jù)

細胞實驗：

DMSO 中的溶解度 : 100 mg/mL (484.78 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制儲備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	4.8478 mL	24.2389 mL	48.4778 mL
5 mM	0.9696 mL	4.8478 mL	9.6956 mL
10 mM	0.4848 mL	2.4239 mL	4.8478 mL

查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用，-20°C儲存時，請在1年內(nèi)使用。

摩爾計算器
稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動物實驗：

請根據(jù)您的實驗動物和給藥方式選擇適當?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (12.12 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (12.12 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (12.12 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液，此方案實驗周期在半個月以上的動物實驗酌情使用。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中，混合均勻。

動物溶解方案計算器

請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

每只動物的給藥體積

μL

動物數(shù)量

只

由于實驗過程有損耗，建議您多配一只動物的量

請輸入您的動物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購。，Tween 80，均可在 MCE 網(wǎng)站選購。

計算結(jié)果

工作液所需濃度 : mg/mL

儲備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。

動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請謹慎選擇該方案。

請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.97%

選擇批次：

Data Sheet (662 KB) SDS (393 KB)

COA (284 KB) LCMS (89 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻

[1]. Noreen Y, et al. Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis. J Nat Prod. 1998 Jan;61(1):2-7. [Content Brief]

[2]. Hassan Akrami, et al. Inhibitory effect of ibuprofen on tumor survival and angiogenesis in gastric cancer cell. Tumour Biol. 2015 May;36(5):3237-43. [Content Brief]

[3]. Sharon M Rymut, et al. Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2016 Aug 1;311(2):L317-27. [Content Brief]

[4]. Emmanuelle Bignon, et al. Ibuprofen and ketoprofen potentiate UVA-induced cell death by a photosensitization process. Sci Rep. 2017 Aug 21;7(1):8885. [Content Brief]

[5]. Nathan D Pennock, et al. Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer. 2018 Oct 1;6(1):98. [Content Brief]

[6]. Thomas Kr?ig?rd, et al. Protective effect of ibuprofen in a rat model of chronic oxaliplatin-induced peripheral neuropathy. Exp Brain Res. 2019 Oct;237(10):2645-2651. [Content Brief]

[7]. Sarah Ilkhanipour Rooney, et al. Ibuprofen Differentially Affects Supraspinatus Muscle and Tendon Adaptations to Exercise in a Rat Model. Am J Sports Med. 2016 Sep;44(9):2237-45. [Content Brief]

[8]. M W Konstan, et al. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis. 1990 Jan;141(1):186-92. [Content Brief]

Ibuprofen 相關(guān)分類

完整儲備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.8478 mL	24.2389 mL	48.4778 mL	121.1945 mL
	5 mM	0.9696 mL	4.8478 mL	9.6956 mL	24.2389 mL
	10 mM	0.4848 mL	2.4239 mL	4.8478 mL	12.1194 mL
	15 mM	0.3232 mL	1.6159 mL	3.2319 mL	8.0796 mL
	20 mM	0.2424 mL	1.2119 mL	2.4239 mL	6.0597 mL
	25 mM	0.1939 mL	0.9696 mL	1.9391 mL	4.8478 mL
	30 mM	0.1616 mL	0.8080 mL	1.6159 mL	4.0398 mL
	40 mM	0.1212 mL	0.6060 mL	1.2119 mL	3.0299 mL
	50 mM	0.0970 mL	0.4848 mL	0.9696 mL	2.4239 mL
	60 mM	0.0808 mL	0.4040 mL	0.8080 mL	2.0199 mL
	80 mM	0.0606 mL	0.3030 mL	0.6060 mL	1.5149 mL
	100 mM	0.0485 mL	0.2424 mL	0.4848 mL	1.2119 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個人或者非科研性質(zhì)的、非用于藥證申報使用等其他用途提供服務(wù)。	站點地圖隱私聲明
滬ICP備15051369號-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2024 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Ibuprofen (Synonyms: 布洛芬; (±)-Ibuprofen)

Customer Review

Other Forms of Ibuprofen:

MCE 顧客使用本產(chǎn)品發(fā)表的 15 篇科研文獻

Ibuprofen 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 COX 亞型特異性產(chǎn)品:

查看 Parasite 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻

摩爾計算器

稀釋計算器

Ibuprofen 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Ibuprofen (Synonyms: 布洛芬; (±)-Ibuprofen)

Customer Review

Other Forms of Ibuprofen:

Ibuprofen 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 15 篇科研文獻

Ibuprofen 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 COX 亞型特異性產(chǎn)品:

查看 Parasite 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻

Ibuprofen 相關(guān)抗體:

摩爾計算器

稀釋計算器

Ibuprofen 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z